Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type
The efficacy of maintenance treatment with PARPi is independent by BRCA domain defects or mutation types. Patients DBD domain defects experienced numerically longer median PFS compared to those with other BRCA1/2 alterations.
Authors
- Maria Rosaria Lamia
- Roberto Buonaiuto
- Aldo Caltavituro (ORCID: https://orcid.org/0000-0001-5952-4333)
- Jole Ventriglia (ORCID: https://orcid.org/0000-0002-8160-5014)
- Carmine De Angelis (ORCID: https://orcid.org/0000-0003-1158-4630)
- Giuseppe Neola
- Giancarlo Troncone (ORCID: https://orcid.org/0000-0003-1630-5805)
- Grazia Arpino (ORCID: https://orcid.org/0000-0002-4074-2530)
- Mario Giuliano (ORCID: https://orcid.org/0000-0003-0835-3153)
- Amedeo Cefaliello
- Francesco Pepe (ORCID: https://orcid.org/0000-0002-2803-9586)
- Alessandra Longobardi
- Sandro Pignata (ORCID: https://orcid.org/0000-0002-8836-2633)
- Umberto Malapelle
- Federica P. Mangiacotti
Institutions
- Federico II University Hospital (IT)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Scuola Superiore Meridionale (IT)
- University of Naples Federico II (IT)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-09-09
- DOI
- https://doi.org/10.3389/fonc.2024.1412807
- Citations
- 8
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 2.26